Stockchase Opinions

Glenn Paradis, BA, CFA Inex Pharmaceuticals Corp IEX-T DON'T BUY Dec 06, 2002

There will be some delay in their filings with FDA.
$4.900

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK
A speculative choice, but has a good RISK/RETURN.
PAST TOP PICK
(Was a top pick on Dec 5 no change) Still likes.
WEAK BUY
In phase 3 trials. Speculative.
BUY
Needs approval by FDA. Nice cash balance.
HOLD
Good cash balance. Their problemsare delays in getting their product to market. Needs a good partner.
DON'T BUY
Need to get FDA approval. Too speculative for their funds.
BUY
If you like biotechs, this could be OK. Speculative.
BUY
A well-run company. Probably one of the lower risk biotech investments in Canada. Their product Onco TCS should be approved this year. Have a good marketing partnership with Enzon.
COMMENT
This is a penny stock and they tend to be promoted.